IVT-8086 / Innova Therapeutics - LARVOL DELTA

Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition (PRNewswire-Asia) - "The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers."

M&A • Hematological Malignancies • Solid Tumor

Innova Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for IVT-8086 for the Treatment of Osteosarcoma (PRNewswire) - “Innova Therapeutics Inc…announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for IVT-8086 for the treatment of Osteosarcoma (OS).”

FDA event • Oncology • Osteosarcoma • Sarcoma